A Radiation-Free Approach Based on the Whole-Body MRI Has Shown a High Level of Accuracy in the Follow-Up of Lymphoma Patients—A Single Center Retrospective Study

Author:

Frolli Antonio12,Varvello Sivlia2,Balbo Mussetto Annalisa3,Gottardi Daniela2,Bullo Martina12,Marini Silvia1,Saglio Giuseppe1,Cirillo Stefano3,Cilloni Daniela1ORCID,Parvis Guido Eugenio2

Affiliation:

1. Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy

2. Division of Hematology, Mauriziano Hospital, 10128 Turin, Italy

3. Division of Radiology, Mauriziano Hospital, 10128 Turin, Italy

Abstract

Background: Recurrence, even after years from the last treatment, characterizes lymphoproliferative disorders. Therefore, patients in complete remission from the disease should be followed up with periodic clinical checks. There is not a consensus on the role of imaging for this aim, because the radiological techniques used at the time of diagnosis expose patients to a risk of ionizing radiation damage. Whole-body magnetic resonance imaging with diffusion-weighted imaging (WB-MRI-DWI) has given similar results to gold standard techniques in detecting lymphoma in the involved sites without ionizing radiation. In this retrospective real-life study, we aimed to assess the accuracy of WB-MRI-DWI during follow-ups of lymphoma patients in terms of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Methods: Lymphoma patients who were subject to at least one WB-MRI-DWI during follow-up between February 2010 and February 2022 were enrolled. Results: Based on our investigation, the calculated sensitivity of WB-MRI-DWI was 100% (95% CI: 99.4–100.0), the specificity was 98.6% (95% CI: 97.4–99.3), PPV was 79% (95% CI: 75.9–81.9), and NPV was 100% (95% CI: 99.4–100.0). Conclusions: Despite the possibility of poor patient compliance and the identification of false positives, WB-MRI-DWI examination demonstrated an excellent sensitivity in ruling out the disease relapse.

Publisher

MDPI AG

Reference26 articles.

1. (2021, November 01). SEER*Explorer: An Interactive Website for SEER Cancer Statistics Surveillance Research Program, National Cancer Institute, Available online: https://seer.cancer.gov/explorer/.

2. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group;Barrington;J. Clin. Oncol.,2014

3. Whole-body PET/CT scanning: Estimation of radiation dose and cancer risk;Huang;Radiology,2009

4. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study;Chien;Int. J. Cancer,2015

5. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022;Hoppe;J. Natl. Compr. Cancer Netw.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3